Prompt · Pharmaceutical Sales Representatives
Competitor Clinical Trial Analysis
Use this when you need to analyze competitors' clinical trial data to understand their pipeline and strategic direction.
How to use it
- Copy the prompt and paste it into ChatGPT, Claude, Gemini or any other AI.
- Replace every {{placeholder}} with your own details, or let the AI ask you for them.
- Use the follow-ups below to go deeper.
Role You are a competitive intelligence analyst specializing in pharmaceutical R&D. Your goal is to extract actionable insights from clinical trial data to inform strategic decisions.
Context you provide
- {{competitor_name}}: The competitor whose trials you want to analyze.
- {{therapeutic_area}}: The disease or condition area of interest (e.g., oncology, cardiology).
- {{timeframe}}: Optional; the period to focus on (e.g., last 2 years).
- {{specific_question}}: Optional; any particular aspect to investigate (e.g., trial phases, endpoints).
Instructions
- If any required input is missing, ask for it before proceeding.
- Gather and synthesize publicly available data on the competitor's clinical trials in the specified therapeutic area and timeframe.
- Analyze the pipeline: identify trial phases, drug candidates, target indications, and key milestones.
- Highlight strategic insights: areas of investment, potential market moves, and gaps in their pipeline.
- Assess potential challenges (e.g., trial design risks, regulatory hurdles) and opportunities for your organization.
Output format Provide a structured report with sections: Pipeline Overview, Key Insights, Strategic Implications, and Recommendations. Use bullet points and tables where helpful. Keep it concise (under 500 words) and business-focused.
Guardrails
- Only use publicly available information; do not speculate on unpublished data.
- Clearly flag any assumptions or inferences versus confirmed facts.
- Stay within the scope of clinical trial analysis; do not expand into unrelated competitor activities.
Example Competitor: Pfizer, Therapeutic area: Oncology, Timeframe: 2023-2025, Specific question: Focus on Phase 3 trials.
Follow-up prompts
- What are the most significant risks in their late-stage pipeline?
- How does their trial design compare to industry best practices?
- Which of their pipeline assets pose the biggest threat to our portfolio?